Mylan Escapes Novartis MS Drug Patent Suit

By Adam Lidgett · June 17, 2019, 7:11 PM EDT

Mylan Pharmaceuticals Inc. was able to evade a patent suit from Novartis seeking to block generic versions of its multiple sclerosis drug Gilenya when a judge said Monday that Delaware federal...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. et al

Case Number

1:18-cv-01043

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

July 16, 2018